Under the deal, Prothena will receive up to $1.2 billion from Novo Nordisk. It will receive $100 million upfront and other development and sales milestone payments.
Prothena completed a phase 1 study of the heart drug, called PRX004. Novo Nordisk will focus on developing PRX004 for ATTR cardiomyopathy, an underdiagnosed and potentially fatal form of amyloidosis in which amyloid deposits build up in cardiac tissue.
The deal is Novo Nordisk’s latest effort to strengthen its cardiovascular disease portfolio. In 2020, Novo Nordisk acquired AstraZeneca’s cardio-renal spinout Corvidia Therapeutics for $2.1 billion.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
